The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice
2007; Springer Science+Business Media; Volume: 14; Issue: 10 Linguagem: Inglês
10.1245/s10434-007-9423-7
ISSN1534-4681
Autores Tópico(s)Metastasis and carcinoma case studies
ResumoAdjuvant Gastric Infusional Chemotherapy (MA-GIC) trial is the first randomized trial to demonstrate a conclusive survival benefit from the use of perioperative chemotherapy for patients with resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus, compared with surgery alone. 1In the intention-to-treat (ITT) analysis, patients who received perioperative chemotherapy with the ECF regimen (epirubicin, cisplatin, and continuous infusion 5-fluorouracil, 5FU) had a 5year survival of 36%, compared with 23% in patients treated with surgery alone (hazard ratio for death, 0.75; 95% confidence interval, 0.60-0.93;P = 0.009).Progression-free survival was also improved by perioperative chemotherapy (hazard ratio for progression, 0.66; 95% confidence interval, 0.53-0.81;P < .001).These results support the use of this treatment strategy as an option for patients with resectable gastric cancer as an alternative to postoperative chemoradiotherapy, which has been shown in a previous randomized trial (the US Intergroup 0116 trial, INT 0116) to also be of benefit in these patients, and are expected to influence the standard treatment of this disease particularly in the UK and Europe. 2
Referência(s)